Eloralintide (5mg)

What Is Eloralintide?

Eloralintide, also known as LY3841136, is an investigational synthetic peptide studied for its activity as a selective, long-acting amylin receptor agonist. Amylin is a naturally occurring peptide hormone involved in appetite regulation and energy balance, and research into eloralintide has focused on its receptor selectivity, pharmacological properties and interactions with biological pathways involved in these processes.

After years of development, eloralintide was introduced publicly in June 2025, attracting interest in its potential application to obesity research and the biological mechanisms governing appetite and body weight. Although early findings have generated interest in eloralintide’s potential, the clinical evidence base is still developing. These early results from trials of an investigational pharmaceutical formulation should not be assumed to apply to separately supplied research materials.

You can now buy Eloralintide 10mg from Crystal Peptides Europe for laboratory research. In keeping with strict quality standards, each batch undergoes independent third-party testing by recognised labs, such as Janoshik, to support quality assessment, for quality parameters such as identity, sterility, endotoxins and heavy metals. Batch-specific Certificates of Analysis (CoAs) are available for review here.

This product is intended exclusively for qualified laboratory research and is not for human or veterinary use.

What's Included?

Eloralintide 5mg is supplied as a lyophilised (freeze-dried) research peptide in a sealed glass vial. The product is provided as a dry powder, not a pre-prepared solution, with the 5mg quantity clearly identified for laboratory research purposes.

Each order includes:

• Product: Eloralintide research peptide
• Quantity: 5mg per vial
• Physical format: Lyophilised powder (not reconstituted)
• Packaging: Sealed glass vial with a rubber septum and aluminium crimp seal.
• Batch documentation: A Certificate of Analysis (CoA) is available for review

For reconstitution, you can order Bac Water (10mL)  or Acetic Acid 0.6% Mixing Water (3ml) also from Crystal Peptides, to be delivered together for convenience.

Eloralintide Technical Specifications

Eloralintide (LY3841136) is a chemically modified amylin analogue designed to provide selective amylin receptor activity and an extended pharmacokinetic profile. Its molecular structure includes a modified 37-amino-acid polypeptide chain, a stabilising methylene thioacetal bridge and a lipidated side chain that supports albumin binding. These structural features distinguish eloralintide from native amylin and other amylin-related research compounds.

Eloralintide's structure has been modified to influence receptor selectivity, chemical stability and pharmacokinetics. The methylene thioacetal bridge replaces the disulfide bridge found in native amylin, while lipidation of the Lys26 residue supports binding to serum albumin. This interaction helps extend the compound's circulation time and supports the once-weekly administration schedule investigated in clinical studies.

Eloralintide: Overview and Mechanism of Action

Eloralintide (LY3841136) is a modified amylin analogue designed to preferentially activate amylin receptors while maintaining a prolonged pharmacokinetic profile. Its mechanism of action is being investigated primarily in relation to amylin receptor signalling, appetite regulation and the biological processes involved in energy balance.

A detailed characterisation of its receptor activity was published in Molecular Metabolism in 2025, which is currently one of the main experimental foundations for understanding how the molecule behaves in cellular and animal models.

Amylin Receptors and Their Role in Cellular Signalling

Amylin is a 37-amino-acid peptide hormone co-secreted with insulin by pancreatic beta cells in response to nutrient intake. It participates in the regulation of appetite, gastric motility and post-meal glucagon secretion. Its effects are mediated through amylin receptors, which are formed when the calcitonin receptor (CTR) associates with one of three receptor activity-modifying proteins (RAMP1, RAMP2 or RAMP3). These combinations produce three receptor subtypes: AMY1R, AMY2R and AMY3R. [1]

The receptor subtype is important because different ligands can exhibit different binding affinities and activation profiles across these receptor complexes. Eloralintide was developed to preferentially activate AMY1R, providing a means of investigating the biological consequences of selective amylin receptor stimulation.

In these studies, receptor activation was assessed using cyclic adenosine monophosphate (cAMP), an intracellular second messenger that can be measured as an indicator of receptor signalling. When eloralintide binds to and activates an amylin receptor, it stimulates downstream signalling detectable through cAMP accumulation in receptor-expressing cells. This provides a quantitative way to compare its potency across different receptor subtypes.

An important point to note is that cAMP activation is a measured indicator of receptor activity, not a complete explanation of every downstream biological effect. The extent to which particular signalling pathways account for changes in appetite, body weight or other physiological outcomes remains a subject of investigation.

Preferential AMY1R Activation and Receptor Selectivity

One of the defining features of eloralintide is its preferential activity at the human AMY1 receptor compared with the human calcitonin receptor and AMY3 receptor. In the published cellular assays, eloralintide was approximately 12 times more potent at activating human AMY1R than CTR and approximately 11 times more potent than AMY3R. Binding assays also demonstrated approximately eightfold greater affinity for human AMY1R than for either of these other receptor targets. [1][2]

These findings distinguish eloralintide from non-selective amylin receptor agonists, which can activate amylin and calcitonin receptor systems to differing degrees. However, preferential activity should not be confused with exclusive receptor activation, since eloralintide demonstrated agonist activity at all three tested human receptor types.

The results also illustrate why receptor selectivity must be interpreted in the context of the experimental system. In rat receptor assays, eloralintide showed a different selectivity profile, with greater relative activity at AMY3R than was observed in the human assays. This species-dependent difference is important when translating findings from animal models to human biology.

For researchers, these data establish receptor potency and binding affinity as distinct but complementary parameters. Potency describes the concentration required to produce a specified response, whereas binding affinity describes the strength of the interaction between a ligand and its receptor; neither measurement alone establishes the magnitude of a physiological effect in a whole organism.

Molecular Modifications and Prolonged Pharmacokinetics

Eloralintide's molecular design incorporates several modifications intended to improve chemical stability and extend its time in circulation. The published structural characterisation describes a 37-amino-acid main chain containing three non-coded amino acid residues, a methylene thioacetal bridge, a lipidated side chain and a C-terminal amide.

The principal modifications have different functions:

• Methylene thioacetal bridge: Native amylin contains a disulfide bridge. Eloralintide replaces this with a methylene thioacetal bridge, which was designed to improve chemical stability.
• Lipidation: A C20 fatty diacid side chain is attached at Lys26 through a linker containing two gamma-glutamate residues. This modification supports reversible binding to serum albumin.
• Albumin binding: Association with circulating albumin helps extend the compound's exposure in the body, contributing to the prolonged pharmacokinetic profile observed in preclinical studies.
• C-terminal amidation: This structural modification forms part of the engineered peptide and distinguishes it from an unmodified native sequence.

Pharmacokinetic studies in rats and cynomolgus monkeys demonstrated higher exposure, a longer half-life and a flatter concentration–time profile for eloralintide compared with cagrilintide under the tested conditions. These findings supported further investigation of an extended dosing interval in clinical studies. [1]

The distinction between receptor pharmacology and pharmacokinetics is important here. The structural modifications influence how the molecule behaves in the body, while receptor interactions determine its pharmacological activity. A longer circulation time does not, by itself, establish greater receptor potency or superior biological outcomes.

Appetite Regulation and Energy Balance in Experimental Models

Amylin receptor signalling is associated with satiety, appetite suppression and the regulation of food intake. Accordingly, preclinical studies of eloralintide have investigated whether its receptor activity is accompanied by measurable changes in feeding behaviour and body composition.

In diet-induced obese rats, eloralintide reduced food intake and body weight in a dose-dependent manner. Body-composition measurements indicated that the reduction in weight was primarily attributable to fat-mass loss in the models examined. These observations provide evidence linking eloralintide's receptor activity to changes in feeding and body-weight regulation, although they do not establish that every effect is mediated by a single downstream pathway. [1][2]

The discovery study also examined conditioned taste avoidance in lean rats, an experimental measure used to investigate aversive responses associated with a treatment. Eloralintide produced significantly less conditioned taste avoidance than cagrilintide in the reported comparison. This finding is relevant to the compound's preclinical behavioural profile, but conditioned taste avoidance is not equivalent to a comprehensive assessment of tolerability in humans.

The precise contributions of central nervous system signalling, peripheral receptor activity and other physiological processes to the observed changes remain under investigation. Consequently, these animal findings should be understood as evidence of pharmacological activity in defined experimental models, not proof of equivalent outcomes in humans.

Eloralintide remains an investigational compound and is supplied exclusively for laboratory research and is not intended nor approved for human or veterinary use.

Eloralintide Research Applications

Research into eloralintide spans receptor pharmacology, appetite regulation, body composition and clinical pharmacology. Its development illustrates how laboratory assays, animal models and human trials contribute different types of evidence when characterising an investigational peptide. The following areas highlight the most relevant research directions without repeating the detailed receptor mechanisms discussed above.

Receptor Pharmacology and Selectivity

Eloralintide has been investigated in cellular systems expressing human and rodent amylin receptor subtypes. Researchers have used receptor-binding assays and cAMP measurements to compare its affinity and functional activity across AMY1R, AMY3R and the calcitonin receptor. [1]

These studies are useful for examining how structural modifications influence receptor preference and whether observed activity differs between species. The published discovery research found preferential activation of human AMY1R, while also identifying differences in the selectivity profile in rat receptor systems. Such findings are important when interpreting preclinical results or comparing eloralintide with other amylin-related compounds.

For researchers, relevant endpoints include receptor-binding affinity, concentration–response relationships and cAMP accumulation. These measurements characterise activity in defined experimental systems but do not independently establish whole-organism effects.

Food Intake and Body-Weight Regulation

Preclinical studies have examined eloralintide's effects on food intake and body weight in lean rats and diet-induced obese rat models. The discovery study reported dose-dependent reductions in food intake and body weight, with body-composition analysis indicating that fat-mass loss accounted for most of the observed weight reduction under the tested conditions. [1]

These experiments provide a basis for investigating the relationship between amylin receptor activity, feeding behaviour and changes in body composition. They also demonstrate why body weight alone may be an incomplete research endpoint, because measurements of fat mass and lean mass can provide better information about the nature of the observed change.

Pharmacokinetics and Formulation Research

Eloralintide's molecular modifications have been investigated in relation to its absorption, systemic exposure and elimination. Studies in rats and cynomolgus monkeys compared its pharmacokinetic profile with that of cagrilintide, while early clinical research examined exposure following single and repeated administration of the investigational pharmaceutical formulation. [1][4]

These studies are relevant to researchers investigating the relationship between peptide structure and pharmacokinetic behaviour. Common endpoints include maximum plasma concentration, total exposure over time, elimination half-life and concentration–time profiles.

Behavioural Measures Related to Tolerability

The discovery study also investigated conditioned taste avoidance in rats, an experimental measure used to assess an aversive response to a treatment. In the reported comparison, eloralintide produced less conditioned taste avoidance than cagrilintide under the tested conditions. [1]

This finding offers a useful example of how preclinical studies can examine behavioural endpoints alongside food intake and body-weight changes. However, conditioned taste avoidance is a model-specific measurement, not a substitute for comprehensive safety or tolerability assessment in humans. Results should be interpreted in the context of the experimental design and the limitations of the model.

Clinical Pharmacology and Translational Research

Clinical studies have extended eloralintide research beyond cellular and animal models. A Phase 1 single-ascending-dose study investigated safety, tolerability and pharmacokinetics in healthy participants, while a separate 12-week Phase 1 study examined repeated once-weekly administration in participants with overweight or obesity.

The multiple-dose study reported dose-proportional drug exposure across the studied cohorts and documented treatment-emergent adverse events, including decreased appetite, headache and fatigue. These findings help characterise the investigational compound's clinical pharmacology, but they do not establish the properties of research-grade material sold separately.

These trials examine outcomes in defined participant populations under controlled conditions; they do not establish efficacy, regulatory approval or the suitability of the compound as a commercial research product.

Eloralintide vs Cagrilintide vs Retatrutide Comparison

Eloralintide, cagrilintide and retatrutide are investigational peptide-based compounds being studied in obesity research, but they differ substantially in their molecular design and receptor targets. Eloralintide and cagrilintide belong to the amylin-related research area, whereas retatrutide is a triple hormone receptor agonist that targets GIP, GLP-1 and glucagon receptors.

While eloralintide has entered Phase 3 trials, cagrilintide is being investigated both independently and in combination with semaglutide, while retatrutide is undergoing Phase 3 evaluation.

Researchers exploring related compounds may also find it useful to explore tirzepatide, a dual GIP/GLP-1 receptor agonist. These compounds provide additional points of comparison for studying how different hormone pathways are investigated in metabolic research.

Eloralintide Storage and Handling

Store and handle the material only under the conditions stated on the label, batch CoA and SDS. Keep the container secured, correctly identified and protected from contamination.

Some of these guidelines include:

• Protection from moisture: Keep the vial tightly sealed and protect the contents from humidity, as moisture can affect peptide stability.
• Light protection: Keep the product in its original packaging or another suitable container that protects it from direct light.
• Temperature fluctuations: Minimise repeated warming and cooling, and avoid leaving the material at room temperature longer than necessary.
• Handling precautions: Use clean laboratory equipment and appropriate personal protective equipment. Avoid direct contact with the material and prevent contamination during handling.
• Reconstitution: Follow laboratory procedures and the relevant product documentation.
• Freeze–thaw cycles: Minimise repeated freeze–thaw cycles where applicable, as these may affect the stability of some peptides.
• Container integrity: Keep the vial properly closed when not in use and inspect the packaging for damage or signs of compromised integrity.
• Shelf life: Observe the stated expiry date and any supplier-provided stability information.
• Disposal: Dispose of unused material and contaminated laboratory consumables in accordance with institutional procedures and applicable regulations.

Always prioritise the supplier’s documentation and any available stability data for the particular batch.

Eloralintide Certificate of Analysis

A Certificate of Analysis (CoA) provides analytical information about a specific product batch, helping researchers assess its reported identity, purity and other tested quality parameters.

Crystal Peptides provides access to laboratory testing reports on the product pages and on the dedicated Lab Tests page. Researchers are encouraged to review the latest CoA for Eloralintide 5mg and confirm that the batch number corresponds to the product supplied.

You can also review the analytical tests performed, which may include methods such as high-performance liquid chromatography (HPLC) for assessing chromatographic purity and mass spectrometry (MS) for supporting molecular identity.

While a CoA supports the evaluation of a research material, it does not by itself establish clinical suitability, biological activity or equivalence to the formulation used in published studies.

For laboratory research only. Not for human or veterinary use.

Frequently Asked Questions About Eloralintide 5mg

What is Eloralintide (LY3841136)?

Eloralintide, also known as LY3841136, is an investigational synthetic peptide studied as a selective, long-acting amylin receptor agonist. Research has examined its receptor activity, pharmacological properties and potential role in biological pathways involved in appetite regulation and energy balance. It is still an investigational compound, and should only be used for laboratory research only.

What is Eloralintide studied for in research?

Eloralintide research has focused on amylin receptor pharmacology, food intake, body-weight regulation and energy balance. Preclinical studies have investigated its effects on food consumption and body composition, while early clinical trials have examined its pharmacokinetics, safety and tolerability, and effects on body weight. Further research is ongoing to clarify its pharmacological properties and potential clinical applications.

What is the difference between Eloralintide and Cagrilintide?

Both Eloralintide and Cagrilintide are long-acting amylin-related peptides, but they differ in their receptor activity profiles. Eloralintide has demonstrated preferential activity at the human AMY1 amylin receptor in published studies, whereas Cagrilintide has a different, less selective receptor profile. Both are investigational compounds. Their research findings should not be used to rank their effectiveness without direct comparative evidence.

Is Eloralintide approved for human use?

Eloralintide remains an investigational compound undergoing clinical evaluation. It is not an approved medicine for routine human use. Crystal Peptides supplies high-purity research materials for laboratory research only, not for human or veterinary use. While there are published clinical trial findings on Eloralintide relating to the investigational formulations studied under controlled conditions, they do not establish the safety or suitability of commercially supplied research material for human use.

Does Eloralintide come with a Certificate of Analysis (CoA)?

When you buy Eloralintide 5mg from Crystal Peptides, you can access laboratory reports on the product page or the Lab Tests page. Analytical testing is typically conducted for each new batch, and you can confirm that the batch number matches the product supplied and results reported. A CoA can support the assessment of identity and purity, along with other parameters where tested, but it does not independently establish clinical suitability or biological activity.

What is the price of Eloralintide 5mg?

Eloralintide 5mg is available from Crystal Peptides at competitive prices. With batch-specific certificates of analysis available, discounts for volume purchases, and free shipping for orders over €200, you get the best value for money. Check the current listing for the latest price, availability and any applicable offers, as these details may change.

Where can I buy Eloralintide 5mg in Europe?

Crystal Peptides is currently offering Eloralintide 5mg for laboratory research use. While availability is currently limited, you can check our online shop for current availability and purchasing information. This material is intended exclusively for laboratory research and must not be used in humans or animals.

References

1. Briere, D. A., Qu, H., Lansu, K., He, M. M., Moyers, J. S., Coskun, T., Long, A., Allen, D., O'Farrell, L., Bowen, B., Pratt, E., Tidemann-Miller, B., Tham, L. S., Ibriga, H., Alsina-Fernandez, J., Mather, K. J., Haupt, A., & Bhattachar, S. N. (2025). Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism, 102, 102271. https://doi.org/10.1016/j.molmet.2025.102271
2. Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2026). Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides, 196, 171480. https://doi.org/10.1016/j.peptides.2026.171480
3. Fischer, S. L., & Borner, T. (2026). Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs. Pharmacological Research, 232, 108382. https://doi.org/10.1016/j.phrs.2026.108382
4. Bhattachar, S., Tham, L. S., Tidemann-Miller, B., Ibriga, H., Qu, H., Briere, D. A., Haupt, A., Mather, K. J., & Pratt, E. (2026). Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism, 28(4), 2651–2660. https://doi.org/10.1111/dom.70439